Literature DB >> 28554528

Lobeline attenuates ethanol abstinence-induced depression-like behavior in mice.

Monzurul Amin Roni1, Shafiqur Rahman2.   

Abstract

Evidence indicates that the brain nicotinic acetylcholine receptor (nAChRs) ligand lobeline reduces depression-like behaviors, ethanol drinking, and nicotine withdrawal-induced depression-like behaviors. The purpose of the present study was to determine the effects of lobeline on ethanol abstinence-induced depression-like behavior and associated neuroadaptive changes in mice. Adult C57BL/6J male mice were allowed to drink 10% ethanol for 4 weeks using a two-bottle choice procedure. Mice were tested after 24 h and 14 days of ethanol abstinence in a forced swim test (FST), a measure for depression-like behavior. Acute lobeline treatment (1 mg/kg) significantly reduced immobility time compared to controls after 24 h and 14 days of abstinence. In addition, abstinence from chronic ethanol exposure reduced serotonin levels in the hippocampus, which was reversed by acute lobeline treatment. Repeated lobeline treatment (1 mg/kg, once daily) for 14 days during ethanol abstinence also significantly reduced FST immobility in mice exposed to ethanol. Chronic ethanol exposure significantly reduced the number of 5-bromo 2'-deoxyuridine (BrdU)-positive cells in the dentate gyrus of the hippocampus, indicating decreased hippocampal cell proliferation. Abstinence from chronic ethanol exposure also decreased brain-derived neurotrophic factor (BDNF) in the dentate gyrus and CA3 region of the hippocampus. In contrast, repeated lobeline treatment significantly increased both BrdU- and BDNF-positive cells. Taken together, our results indicate that lobeline produced antidepressant-like effects, likely by targeting brain β2-containing nAChRs, serotonergic neurotransmission, and/or hippocampal cell proliferation. Therefore, lobeline may have therapeutic utility to treat alcohol abstinence-induced depression.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcohol; Hippocampus; Lobeline; Major depression; Mice; Nicotinic receptor

Mesh:

Substances:

Year:  2017        PMID: 28554528     DOI: 10.1016/j.alcohol.2017.01.015

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  6 in total

1.  Alcohol withdrawal drives depressive behaviors by activating neurons in the rostromedial tegmental nucleus.

Authors:  Rao Fu; Wanhong Zuo; Nimisha Shiwalkar; Qinghua Mei; Qing Fan; Xuejun Chen; Jing Li; Alex Bekker; Jiang-Hong Ye
Journal:  Neuropsychopharmacology       Date:  2019-03-31       Impact factor: 7.853

2.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) alleviates depression-like behavior and normalizes epigenetic changes in the hippocampus during ethanol withdrawal.

Authors:  Wei-Yang Chen; Huaibo Zhang; Eleonora Gatta; Elizabeth J Glover; Subhash C Pandey; Amy W Lasek
Journal:  Alcohol       Date:  2019-03-06       Impact factor: 2.405

3.  Drinking Pattern in Intermittent Access Two-Bottle-Choice Paradigm in Male Wistar Rats Is Associated with Exon-Specific BDNF Expression in the Hippocampus During Early Abstinence.

Authors:  Danil Peregud; Mikhail Stepanichev; Natalia Gulyaeva
Journal:  J Mol Neurosci       Date:  2020-06-26       Impact factor: 3.444

4.  Epigenetic mechanisms underlying stress-induced depression.

Authors:  Luana Martins de Carvalho; Wei-Yang Chen; Amy W Lasek
Journal:  Int Rev Neurobiol       Date:  2020-09-26       Impact factor: 3.230

5.  From cis-Lobeline to trans-Lobeline: Study on the Pharmacodynamics and Isomerization Factors.

Authors:  Huan-Hua Xu; Liang Yang; Ming-Xia Tang; An-Ping Ye; Bo-Dan Tu; Zhen-Hong Jiang; Jian-Feng Yi
Journal:  Molecules       Date:  2022-09-22       Impact factor: 4.927

6.  Synaptic Ultrastructure Might Be Involved in HCN1-Related BDNF mRNA in Withdrawal-Anxiety After Ethanol Dependence.

Authors:  Lanwei Hou; Yujuan Guo; Bo Lian; Yanyu Wang; Changjiang Li; Gang Wang; Qi Li; Jinjing Pang; Hongwei Sun; Lin Sun
Journal:  Front Psychiatry       Date:  2018-05-29       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.